Chongqing Juqinuomei Pharmaceutical

Chongqing Juqinuomei Pharmaceutical is a clinical-stage biotechnology company based in Chongqing, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company focuses on targeting G-protein coupled receptors (GPCRs), with a particular emphasis on the incretin system to address global health challenges like type 2 diabetes and obesity. Its lead candidate, JQN-010, is an orally available small molecule GLP-1 receptor agonist currently undergoing Phase 1 clinical trials. Juqinuomei aims to differentiate itself by providing potent, orally bioavailable alternatives to traditional injectable peptide therapies. The company's pipeline also includes multi-target agonists designed to treat complex metabolic conditions including nonalcoholic steatohepatitis (NASH).